Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
DUBLIN, Ireland, Aug. 01, 2017 -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six months of 2017 on August 8, 2017 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully-integrated research, development and commercial capabilities. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena seeks to fundamentally change the course of progressive diseases associated with this biology. The Company’s pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002/RG7935), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company’s website at www.prothena.com
Media & Investor Contact: Ellen Rose, Head of Communications 650-922-2405, [email protected]
